Cargando…
Bone-targeted methotrexate–alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo
Rheumatoid arthritis (RA), a disease that causes joint destruction and bone erosion, is related to osteoclast activity. RA is generally treated with methotrexate (MTX). In this study, a MTX–Alendronate (ALN) conjugate was synthesized and characterized. The conjugate dramatically inhibited osteoclast...
Autores principales: | Xie, Zi’ang, Liu, Guanxiong, Tang, Pan, Sun, Xuewu, Chen, Shuai, Qin, An, Zhu, Peizhi, Zhang, Jianfeng, Fan, Shunwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058523/ https://www.ncbi.nlm.nih.gov/pubmed/29303005 http://dx.doi.org/10.1080/10717544.2017.1422295 |
Ejemplares similares
-
The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorption, but without affecting bone formation
por: Chen, Wenxiang, et al.
Publicado: (2019) -
Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice
por: Huang, Bao, et al.
Publicado: (2019) -
The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
por: Li, Xiang, et al.
Publicado: (2019) -
Modifying collagen with alendronate sodium for bone regeneration applications
por: He, Yingcong, et al.
Publicado: (2018) -
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
por: Le Goff, Benoit, et al.
Publicado: (2009)